Strategies for Effective Solubilization & Bioavailability Enhancement of BCS Class Type II and Type IV APIs

HEALTH CARE



Public

Industrial & Consumer Specialties Health Care

what is precious to you?

CLARIANT

Clariant has the wide product portfolio for Excipients and Polyglykols as Active Pharmaceutical Ingredients (APIs)





Top quality range of Polyglykols (Polyethylene Glycols - PEGs) used as Active Pharmaceutical Ingredients (APIs) in laxatives formulations and in ophthalmic preparations

Excipients



Comprehensive range of excipients (Motusflex® and VitiPure®) such as Solubilizers, Emulsifiers, Solvents, Rheology Modifiers, Binders, Humectants, Plasticizers etc. for all sorts of pharmaceutical dosage formulations.

CLARIANT

Clariant with a worldwide Pharmaceutical Manufacturing Facilities, R&D and commercial offices



Research & Innovation Center

Frankfurt & Shanghai

Pharma Manufacturing sites

- Gendorf & Dayabay: Polyglykols[®], VitiPure™ mPEGs
- Tarragona: VitiPure[™], Motusflex[®]

Commercial Offices

 Across multiple countries: USA, Brazil, Germany, France, Italy, UK, UAE, Turkey, China, Singapore, India, Australia, etc.

Our positive and progressive track-record in the health Care industry encouraged us to become the best-in-class solution provider

TOP SUPPLIERS BY CUSTOMER LOYALTY: SATISFACTION, LIKEHOOD TO RECOMMEND & RE-PURCHASE¹



SOURCE: Expert interviews, Team analysis

1 Data published in ISR reports shown as the top 10 companies with the biggest loyal customer base. Loyalty is a combination of other three factors: 1. Overall satisfaction, 2. Likelihood to recommend and 3. Likelihood to use again



Challenges in Pharma Industry

- About 40% of NCEs are poorly water soluble
- A significant percentage cannot be absorbed effectively due to their complex chemical structures or absorption profiles"


"41% of NCE developments fail due to poor bio-pharmaceutical properties"







90% of APIs Are Poorly Soluble API Classification





Permeability

Benet, EDAN, Leuven, March 18-20 2007



How Can Clariant Help You To Get A Solution?

Using our solubilizers will increase your performance!

Which groups of solubilizers do we offer?

- 1. Solvents
- 2. PEG- Derivatives
- 3. Poloxamer





New Solubilizers by Clariant

	Name	Pharmacopeial name	Monograph
Solvents	VitiPure LEX 300/ 400	Polyethylene Glycol 300/ 400 Macrogol 300/ 400	USP/NF Ph.Eur. JP
PEG- Derivatives	VitiPure HCO 40	Polyoxyl 40 Hydrogenated Castor Oil Macrogolglycerol Hydroxystearate	USP/NF Ph.Eur
	VitiPure CO 35	Polyoxyl 35 Castor Oil Macrogolglycerol Ricinoleate	USP/NF Ph.Eur
	VitiPure L 20	Polysorbate 20	USP/NF Ph.Eur.
	VitiPure O 80	Polysorbate 80	USP/NF Ph.Eur.
Poloxamer	VitiPure P 188	Poloxamer 188	USP/NF Ph.Eur.



VitiPure LEX 300 / 400 Widely Used Solvent With Stringent Control of Microbial Load



Public

Industrial & Consumer Specialties Health Care

what is precious to you?



VitiPure[™] LEX 300/400 – Description

ΙV	
	i = 1
	$i \equiv l$

GENERIC NAMES	Macrogol in Ph.Eur., JP and Polyethylene glycol in USP/NF
 TYPE 	Polyethylene Glycol 300 & Polyethylene Glycol 400
APPEARANCE	Clear Liquid

- CAS NO. 25322-68-3
- SAFETY
- World-wide several registered Pharmaceutical OTC and prescription medicines

Listed in the inactive ingredient database of the FDA

- RETEST PERIOD 2 years
- PACKAGING SIZES* 220kg & 30kg (Stainless steel drum with PE-inliner)

Sample size 0.5kg



VitiPure[™] LEX 300 / 400 - Key Information



Microbial Specifications in Addition to Ph.Eur., JP and USP/NF Specifications

+ Endotoxin	max. 1 IU/ml
+ TAMC	max. 50 cfu/g
+ TYMC	max. 50 cuf/g
+ Salmonella	absent
+ Staphylococcus aureus	absent
+ Escherichia coli	absent
+ Pseudomonas aeruginosa	absent



VitiPure[™] LEX 300 / 400 - Applications



- Safe and widely used pharmaceutical solvents for varieties of different APIs which are difficult to dissolve in water
- Applied in liquid and semi-solid formulations
- Excellent hygroscopicity, perfect as humectants



VitiPureTM LEX 300 / 400

DOSAGE & APPLICATIONS



13



FDA Published Applications For Polyethylene Glycol 300 Dosage and Applications*



 Auricular (OTIC) Upto. 97.43% w/v



Ophthalmics**
 Upto. 0.5 – 1% w/v



 Tablets/Capsules Upto. 9 mg



Creams
 Upto. 57% w/w



 Injection** Upto. 65% w/v

*Published in Inactive Ingredients Database by FDA

** Requires parenteral grade



FDA Published Applications For Polyethylene Glycol 400 Dosage and Applications*



Oral Solutions
 upto. 74mg/1ml



 Ophthalmics** upto. 4% w/v



 Tablets/Capsules upto. 324.5 mg



• Ointment upto. 65% w/w



 Injection** IM: upto. 20.3% w/v IV: upto. 75.58% w/v



 Suppository upto. 30mg



 Nasal upto. 27mg

*Published in Inactive Ingredients Database by FDA

** Requires parenteral grade



VitiPure[™] LEX 300 / 400 - Benefits



- Low microbial load for high-risk applications
- Surpass the current pharmacopoeia requirements
- Supports risk assessment in pharmaceutical and biopharmaceutical manufacturing



Non-Ionic Solubilizers

Based on PEG-Derivatives



Public


Industrial & Consumer Specialties Health Care

what is precious to you?

CLARIANT

Characterization of non-ionic solubilizers


HLB value (Hydrophilic - Lipophilic - Balance)





18



Solubilizer – PEG - Derivatives Overview – Structure and Principle of Micellization










Public

Industrial & Consumer Specialties Health Care

what is precious to you?

CLARIANT

VitiPure[™] HCO 40 – Chemistry structure



21



VitiPure[™] HCO 40 – Description

$\square =$
$\overline{\square} =$
$\overline{\square} =$

GENERIC NAMES

Polyoxyl 40 Hydrogenated Castor Oil (USP) Macrogolglycerol Hydroxystearate (Ph. Eur.)

- TYPE Non-ionic surfactant
- CAS NO. 61788-85-0
- SAFETY World-wide several registered Pharmaceutical OTC and prescription medicines

Listed in the inactive ingredient database of the FDA

- GMP IPEC
- RETEST PERIOD 2 years
- PACKAGING SIZES* 100kg steel drum (epoxy coated in-liner) and 25kg steel drum (epoxy coated in-liner)

Sample size 0.5kg



VitiPure[™] HCO 40 – Properties



- HLB VALUE
- PHYSICAL PROPERTIES
- CRITICAL MICELLE CONCENTRATION
- ORGANOLEPTIC PROPERTIES
- SOLUBILITY

14 - 16

yellowish to white paste at 20°C

0.03% w/w at 37°C (in water)

practically no odor or taste

forms clear solutions in water, ethanol, 2-propanol, npropanol, ethyl-acetate, chloroform, carbon tetrachloride, toluene and xylene

STABILITY

aqueous VitiPure HCO 40 solutions are stable can be sterilized by heating to 120°C



VitiPure[™] HCO 40

DOSAGE & APPLICATIONS





FDA Published Applications For PEG 40 HCO Dosage and Applications*



• Oral Solutions Upto. 0.5 – 45%



Ophthalmics
 Upto. 0.5 – 1% w/v



 Tablets/Capsules (MDE**) 120 mg / 3319 mg



Creams
 Upto. 1% w/w



 Softgel capsules Upto. 400 mg

*Published in Inactive Ingredients Database by FDA



Versatile Solubilizer For A Wide Range Of Applications


Drug Form	Important Functions
Solutions / gels / cremes	 Solubilization by inclusion in small micelles (→ microemulsion)
Emulsions	 Emulsification by inclusion in big micelles (→ macroemulsion) Ideal solubilizer & Emulsifier for hydrophobic APIs and Vitamins
Suspensions	Increase of wettabilityReduction of sedimentation
Tablets / capsules / suppositories	 Increase of bioavailability by solubilization in the gastro-intestinal tract



Improving the Solubility of Fat-Soluble Vitamin D

Aqueous solution of Vit D


- 0.8 g Vitamin D2 (400 000 I.U.) or
- 0.5 g Vitamin D3 (125 000 I.U.)
- 100ml water
- 6g PEG 40 HCO



27



Application of VitiPure[™] HCO 40 into SEDDS



Cuine et al., Pharm. J Pharm. Sci, Vol 97, No. 2, 2008


- Crossover (7day wash-out) study in four beagle dogs (male)
- Treatment administered in 2 x 800mg (soft gelatine capsules)
- API Danazol at 80% saturated solubility included in formulation



VitiPure[™] HCO 40 – Key benefits



- Ideal solubilizer & emulsifier for hydrophobic APIs and Vitamins
- Safety & toxicology well established via several marketed drugs world wide
- Suitable for SEDDS* and SMEDDS** formulations
- Zero taste and odour perfect for oral applications





Public

Industrial & Consumer Specialties Health Care

what is precious to you?




VitiPure[™] CO 35 - Description

ഫ

•	GENERIC NAMES	Polyoxyl 35 Castor Oil <i>(USP)</i> Macrogolglycerol Ricinoleate <i>(Ph. Eur.)</i>
•	TYPE	Non-ionic surfactant
•	CAS NO.	61791-12-6
•	SAFETY	World-wide several registered Pharmaceutical OTC and prescription medicines
		Listed in the inactive ingredient database of the FDA
•	GMP	IPEC
•	RETEST PERIOD	2 years
•	PACKAGING SIZES*	100kg steel drum (epoxy coated in-liner) and 25kg steel drum (epoxy coated in-liner)
		Sample size 0.5kg

CLARIANT

VitiPure[™] CO 35 – Chemistry structure



32



VitiPure[™] CO 35 – Properties

HLB VALUE



- 12 14
- PHYSICAL PROPERTIES
- CRITICAL MICELLE
 CONCENTRATION

12 11

Pale yellow or clear liquid depending on the temperature

- 0.02% w/w at 37°C (in water)
- ORGANOLEPTIC PROPERTIES Faint characteristics odor
- SOLUBILITY forms clear solutions in water, ethanol, 2-propanol, n-propanol, ethyl-acetate, chloroform, carbon tetrachloride, trichloroethylene, toluene and xylene
- STABILITY aqueous VitiPure CO 35 solutions are stable can be sterilized by heating to 120°C

Industrial & Consumer Specialties, Health Care



VitiPure[™] CO 35

DOSAGE & APPLICATIONS



34



FDA Published Applications For PEG 35 CO Dosage and Applications*



24945mg (MDE)


*Published in Inactive Ingredients Database by FDA per unit dose MDE: Maximum daily exposure **Requires parenteral grade



Less VitiPure CO 35 is Required to Dissolve Equal Amount of Fat-Soluble Vitamin E Compared with Polysorbate 80

Aqueous solution of Vit E

- 15 g Vit E acetate
- 100ml water
- 30g Solubilizer






VitiPure CO 35 - Solubilisation Capacity of Paclitaxel

Effect of the formulation vehicle on paclitaxel concentration in female mice receiving paclitaxel at a dose of 10mg/kg.

(DMA: Dimethylacetamide)




Zordan-Nudo et al, Cancer Res., Vol 56, 1996



VitiPure[™] CO 35 – Key Benefits



- Emulsifies or solubilizes the fat-soluble vitamins A, D, E and K in aqueous solutions for oral and topical administration.
- Aqueous solutions of hydrophobic drugs (e.g. Miconazole, Hexedetine, Clotrimazole, Benzocaine etc.) can be prepared using VitiPure CO 35
- Safety & toxicology well established via several marketed drugs world-wide into human and veterinary medicines and nutrition.
- Increases bioavailability when used in SEDDS





Public

Industrial & Consumer Specialties Health Care

what is precious to you?



VitiPureTM L 20 / O 80 - Description

[_			_1
	4	=	-1
١C	2	=	=
١Ē	7	_	=
		<u>S</u> SS	

 GENERIC NAMES 	Polysorbate 20 <i>(USP/NF; Ph. Eur.)</i> Polysorbate 80 <i>(USP/NF; Ph. Eur.)</i>
• TYPE	Non-ionic surfactant
• CAS NO.	VitiPure L 20 (9005-65-5); VitiPure O 80 (9005-65-6)
 SAFETY 	World-wide several registered Pharmaceutical OTC and prescription medicines Listed in the inactive ingredient database of the FDA
■ GMP	IPEC
RETEST PERIOD	2 years
 PACKAGING SIZES 	100kg steel drum (epoxy coated in-liner) and 25kg steel drum (epoxy coated in-liner)
	Sample size 0.5kg

40



VitiPure[™] L 20 / O 80 – Properties



- HLB VALUE
- PHYSICAL
 PROPERTIES


16.7 (VitiPure[™] L 20) / 15.0 (VitiPure[™] O 80)

Viscous clear liquid

- CRITICAL MICELLE 0.006% w/w at 37°C (in water) (VitiPure[™] L 20) / 0.002% w/w at (in water) (VitiPure[™] O 80)
- SOLUBILITY
- It is readily soluble in water and alcohols, it is insoluble in oils.

CLARIANT


VitiPure™ L 20 / O 80 – Chemistry structure





VitiPureTM L 20 / O 80

DOSAGE & APPLICATIONS





FDA Published Applications For Polysorbate 20 Dosage and Applications*

Upto. 4.2 mg



*Published in Inactive Ingredients Database by FDA **Parenteral grade is required



FDA Published Applications For Polysorbate 80 Dosage and Applications*



*Published in Inactive Ingredients Database by FDA

IA: Intra-articular; IB: Intrabursal; IL: Intralesional; IM: Intramuscular; IS: Intrasynovial; IV: Intravenous; IV:Intravitreal; SC: Subcutaneous ** Pareteral grade is required



VitiPure[™] L 20 / VitiPure[™] O 80 – Typical Applications









Public

Industrial & Consumer Specialties Health Care

what is precious to you?



VitiPure[™] P 188 – Description

- GENERIC NAMES
- Poloxamer (USP) Poloxamers (Ph. Eur.)
- TYPE Non-ionic surfactant
- CAS NO. 9003-11-6
- SAFETY World-wide several registered Pharmaceutical OTC and prescription medicines Listed in the inactive ingredient database of the FDA
- GMP IPEC
- RETEST PERIOD 2 years
- PACKAGING SIZES* 100kg Plastic drums (with PE bag in-liner) and 25kg Plastic drums (with PE bag in-liner)

Sample size 0.5kg



VitiPureTM P 188 – Properties

HLB VALUE



• PHYSICAL PROPERTIES Waxy Powder (Flakes)

29

- CRITICAL MICELLE CONCENTRATION
- 0.07% w/w at 37°C (in water)

SOLUBILITY


Readily soluble in water, Polar and non-polar solvents



VitiPureTM P 188 – Composition




- Poloxamers are synthetic copolymers of polyoxyethylene (POE) and polyoxypropylene (POP) units
- Chemical composition: A B A triblock-polymer





Mechanism of Complexation of Poloxamers



- Micelles are composed of a compact core of "insoluble" POP blocks and a highly swollen shell of "soluble" POE blocks.
- Micelles have spherical shape.
- Inner core radius and solubilization capacity of a specific poloxamer is dictated by the length of the POP – part of the poloxamer.

Industrial & Consumer Specialties, Health Care



VitiPure™ P 188

DOSAGE & APPLICATIONS



52



FDA Published Applications For Poloxamer 188 Dosage and Applications*



 Oral Solutions upto 100mg/1ml



• Ophthalmics upto 0.1% w/v



 Tablets/Capsules upto 66.9 mg



 Creams upto 1% w/w



Injection** IM: 0.2% w/v IV: 6mg




 Periodontal Gel upto 55mg

*Published in Inactive Ingredients Database by FDA per unit dose **Parenteral grade is required



VitiPureTM P 188 – Typical Applications








VitiPure[™] P 188 – Improvement of API dissolution

Dissolution profiles of different formulations of Rofecoxib and Poloxamer 188




Shah et al., AAPS Pharm. Sci. Tech., Vol 8, No.2, 2007

Optimized formulation: solid dispersion (melt granulation)



VitiPure[™] P 188 – Improvement of API dissolution

Influence of Poloxamer 188 on the bioavailability in humans of orally administered Griseofulvin (250 mg)



Heyer and Frömming, DAZ, Vol 123, No.18, 1983



VitiPure[™] P 188 – Key Benefits



- Multi-talent solubilizer for variety of applications
- Safety & toxicology well established via several marketed drugs world-wide into human and veterinary medicines and nutrition.
- Suitable in solid dispersions and improves the solubility, absorption and bioavailability of low-solubility APIs in solid oral dosage forms.

CLARIANT

Disclaimer

This information reflects our current state of knowledge and only represents a general description of our products and their possible applications. Clariant assumes no liability for the completeness, correctness, accuracy, and suitability of this information and use of this information. It is the user's responsibility to assess whether a Clariant product is suitable for a specific application.* Unless agreed otherwise in writing, Clariant's general terms and conditions of sale, which are not modified or invalidated by this information, shall apply. The rights of third parties shall be observed. Clariant reserves the right to modify this information and the product information at any time, in particular as a result of changes to legal provisions. Safety data sheets, which include the safety measures to be observed when storing or handling Clariant products, are supplied with the delivery. For additional information, please contact Clariant.

* For sales to customers located within the United States and Canada the following applies in addition: NO EXPRESS OR IMPLIED WARRANTY IS MADE OF THE MERCHANTABILITY, SUITABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE OF ANY PRODUCT OR SERVICE.

® Trademark of Clariant registered in many countries of the world
 © 2020 Clariant International Ltd

Industrial & Consumer Specialties, Health Care







59



* **BCS Classes:** The Biopharmaceutics Classification System is a system to differentiate the drugs on the basis of their solubility in water and intestinal permeability. This classification is limited to oral administered drugs.

Class I - high permeability, high solubility

Example: paracetamol. Those compounds are well absorbed and their absorption rate is usually higher than excretion.

Class II - high permeability, low solubility

Example: glibenclamide, bicalutamide, ezetimibe, aceclofenac.

The bioavailability of those products is limited by their solvation rate.

Class III - low permeability, high solubility

Example: cimetidine. The absorption is limited by the permeation rate but the drug is solvated very fast.

Class IV - low permeability, low solubility

Example: Bifonazole. Those compounds have a poor bioavailability. Usually they are not well absorbed over the intestinal mucosa and a high variability is expected.



* Bioavailability:

Describes the fraction of an administered dose of a pre-metabolized drug that reaches the systemic circulation; one of the principal drug pharmacokinetic properties. A drug is bioavailable if the pharmaceutical form releases the API to the body in a time limit.

In the case of tablet forms, e.g, => bioavailability includes but is not limited to:

- tablet disintegration (cleavage)
- dissolution of API in the medium (solubilization),
- body absorption, linked to API permeation.

If there is no cleavage and/or no solubilization => no body absorption...



* **Solubilization:** action of splitting in a liquid a substance into its molecular state; the result called solution is a homogenous single phase.

* **Solubility** is a physical property referring to the ability for a given substance, the solute, to dissolve in a solvent. It is measured in terms of the maximum amount of solute dissolved in a solvent at equilibrium. The resulting solution is called a saturated solution. Certain substances are soluble in all proportions with a given solvent, such as ethanol in water. This property is known as miscibility.

* Poorly soluble drugs: <1 mg/ml.

* **Dispersion:** action of splitting an insoluble substance into small particles in a liquid. This leads to a biphasic preparation. Some examples are: emulsions, suspensions, foam...



* **SEDDS:** Self-emulsifying drug delivery systems (SEDDS), which are isotropic mixtures of oils, surfactants, solvents and co-solvents/surfactants, can be used for the design of formulations in order to improve the oral absorption of highly lipophilic drug compounds.

In order to effectively make such formulations, high concentrations of surfactant, oil and aqueous phase are mixed. The resultant formulations are clear, low-viscosity, isotropic and suitable for encapsulation into softgels, hard shell capsules and other liquid formulations.

Once the formulations are released inside the GIT, they emulsify into nanoscale (15 – 80 nm) droplets, which are further digested and absorbed, significantly increasing bioavailability.



* NCE: New Chemical entity. It is new drug (Active pharmaceutical ingredient) which do not have market presence and is not registered.

* **SMEDDS**: A self-microemulsifying drug delivery system (SMEDDS) is a drug delivery system that uses a microemulsion achieved by chemical rather than mechanical means. SMEDDS are of particular value in increasing the absorption of lipophilic drugs taken by mouth.

* MDE: Maximum Daily Exposure (MDE) is the total amount of the excipient that would be taken or used in a day based on the maximum daily dose (MDD) of the drug product in which it is used. MDE is calculated as the dosage unit level of the excipient multiplied by the maximum number of dosage units recommended per day (excipient (mg) x number units). MDE may also be referred to as maximum daily intake (MDI) for oral drug products.

64